The aim of the present study was to investigate the prognostic impact of BRAF-V600 tumor mutations in melanoma patients receiving first-line treatment with dacarbazine or temozolomide during the years 2000–2010, before availability of BRAF inhibitors. This evidence concerns the gene BRAF and melanoma.